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Promoter analysisbeta (TGF-β1) promotes cartilage matrix synthesis and induces tissue inhibitor of
metalloproteinases-3 (TIMP-3), which inhibits matrix metalloproteinases, aggrecanases and TNF-α-converting
enzyme implicated in articular cartilage degradation and joint inﬂammation. TGF-β1 activates Akt, ERK and
Smad2 pathways in chondrocytes. Herewe investigated previously unexplored roles of speciﬁc Smads in TGF-β1
induction of TIMP-3 gene by pharmacological and genetic knockdown approaches. TGF-β1-induced Smad2
phosphorylation and TIMP-3 protein expression could be inhibited by the Smad2/3 phosphorylation inhibitors,
PD169316 and SB203580 and by Smad2-speciﬁc siRNA. Speciﬁc inhibitor of Smad3 (SIS3) and Smad3 siRNA
abolished TGF-β induction of TIMP-3. Smad2/3 siRNAs also down regulated TIMP-3 promoter-driven luciferase
activities, suggesting transcriptional regulation. SiRNA-driven co-Smad4 knockdown abrogated TIMP-3
augmentation by TGF-β. TIMP-3 promoter deletion analysis revealed that −828 deletion retains the original
promoter activity while −333 and −167 deletions display somewhat reduced activity suggesting thatmost of the
TGF-β-responsive, cis-acting elements are found in the −333 fragment. Chromatin Immunoprecipitation (ChIP)
analysis conﬁrmed binding of Smad2 and Smad4 with the −940 and −333 promoter sequences. These results
suggest that receptor-activated Smad2 and Smad3 and co-Smad4 critically mediate TGF-β-stimulated TIMP-3
expression in human chondrocytes and TIMP-3 gene is a target of Smad signaling pathway.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionDegradation of cartilage extracellular matrix (ECM) by proinﬂam-
matory cytokine-stimulated matrix metalloproteinases (MMPs) and
aggrecanases (ADAMTS or A Dystrophin And Metalloproteinase with
ThromboSpondin motif) [1,2] is observed in inﬂammatory rheumatoid
arthritis (RA) and aging-associated osteoarthritis (OA), the most pro-
minent forms of arthritis in clinic [3,4]. Cartilage from older patients has
limited capacity to regenerate due to reduced transforming growth factor
beta (TGF-β) and its type II receptor, and resulting chondrocyte
hyporesponsiveness [5]. TGF-β super-family members stimulate chon-
drogenesis during development andmaintain cartilage integrity in adults
[6,7]. In rat models, it suppresses acute and chronic arthritis by counter-
acting the effects of the proinﬂammatory, interleukin-1 (IL-1) [8]; an
observation not reproduced in older mice [9]. Elevated TGF-β in human
rheumatoid synovial ﬂuid activates synovialﬁbroblasts, which ultimately
invade and destroy cartilage [10,11]. As a side effect, excessive TGF-β
induces formation of osteophytes, the joint outgrowths, which limit joint
movement and cause pain [12]. Inhibition of endogenous TGF-β by
scavenging type II receptor or by its signaling antagonist, Smad7, in a; fax: +1 514 412 7612.
a (M. Zafarullah).
l rights reserved.papain-inducedmurine arthritis model prevented osteophyte formation,
synovial thickening and impaired cartilage repair, suggesting its crucial
role in these pathological and physiological processes [7,13]. In a rabbit
model, however, TGF-β failed to repair cartilage and induced adverse
effects such as cartilage degradation, muscle edema, ﬁbrogenesis and
chondrogenesis in the synovial linings [14]. Multiple TGF-β injections
increased and decreased proteoglycan content in the superﬁcial and
deep zones ofmurine cartilage respectively and inducedOA-like changes.
Thus, in small amounts, TGF-β suppresses arthritis and promotes carti-
lage remodeling [7]. TGF-β1 is also a favorite stimulus for regenerating
high-quality cartilage by in vitro and in vivo gene therapy and tissue
engineering [15].
TGF-β exerts its effects by inducingmultiple genes including tissue
inhibitor of metalloproteinase-3 (TIMP-3), a member of TIMP family
of proteins [16]. TIMP-3 protein is uniquely located in ECM where its
N- and C-terminal domains bind to chondroitin- and heparan sulfate
[17]. In cartilage explants, TIMP-3 inhibits MMP-13 and ADAMTS4,
the principal proteases degrading collagen and aggrecan in arthritis
[18,19]. It also inhibits theTNF-α convertingenzyme (TACEorADAM-17)
[20] that activates membrane-bound precursor of proarthritic cytokine,
TNF-α into soluble secreted form [21,22]. Thus, TIMP-3 can regulate
TNF-α-driven inﬂammation. TIMP-3 knockout mice display an in-
creased initial inﬂammation and TNF-α level in the antigen-induced
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more susceptible to age-dependent cartilage degradation [23,24]. These
distinct features make TIMP-3 a potentially important therapeutic
protein inarthritis [25]. Indeed, TIMP-3overexpressionprevents invasion
of cartilage by human rheumatoid synovial ﬁbroblasts in amousemodel
[26].
Due to therapeutic potential of TIMP-3, it is important to under-
stand the mechanisms of TGF-β induction of TIMP-3. In other cell
types, TGF-β ﬁrst binds with type II receptors and then phosphor-
ylates and activates type I receptor on serine and threonine, leading to
transcription of the target genes via stimulatory Smad2/3 and co-
Smad4 [27]. Recently, TβRII-B a type II receptor variant was found to
complex with other TGF-β receptors such as betaglycan and endoglin
to enhance signal transduction [28]. Smad2 and −3 are found in
associationwith proliferating andmaturing chondrocytes respectively
[29]. Smad3 knockout mice display OA-like symptoms [30]. We
previously showed Smad2 phosphorylation by TGF-β in bovine and
human chondrocytes [31]. Subsequently, we demonstrated the es-
sential role of extracellular-signal-regulated kinase (ERK)-mitogen-
activated protein kinases (MAPK), PI3K/Akt pathway and Sp1
transcription factor in TGF-β-induced TIMP-3 gene in chondrocytes
[32,33]. Here we show for the ﬁrst time that speciﬁc Smads are critical
in TIMP-3 promoter regulation by TGF-β.
2. Experimental procedures
2.1. Cell culture and treatments
Normal human knee chondrocytes (Cambrex, Walkerville, MD) were grown in
Differentiation Bullekit medium as high-density short-term monolayer cultures in 6-well
plates up to passages 2 and 3. Under these culture conditions, they continue to expressFig. 1. PD169316 and SB203580 but not the inactive analogue, SB202474 inhibit TGF-β-induce
beta-actin levels in human articular chondrocytes. Quiescent conﬂuent chondrocytes were
pretreated with 5 or 10 µM of PD169316, SB203580 and SB202474 alone for 60 min and then
panels are phospho- (p-Smad2) and total Smad2 B) p-Smad3 and total Smad3 Western blot
graphs show normalized densitometric values of pSmad-2, pSmad3 and TIMP-3 protein
experiments. Pb0.05 was considered signiﬁcant.collagen II, a marker of differentiated chondrocytes [33]. Following conﬂuent growth,
chondrocytes were maintained in serum-deﬁcient Dulbecco's modiﬁed Eagle's medium
(DMEM) (Invitrogen Life Sciences Inc, Burlington, ON) for 24 h and subjected to different
treatments. In some cases, chondrocytes were pretreated in serum-free mediumwith the
Smad2/3pharmacological inhibitors, PD169316, SB203580, SB202474or SIS3 (Calbiochem,
La Jolla, CA) for 60 min and then stimulated with 10 ng/ml of TGF-β1 (R & D Systems,
Minneapolis MN) for 20 min (for Smad phosphorylation) or 24 h (for TIMP-3 protein
expression). Control cells received equivalent amounts of the vehicle, dimethyl sulfoxide
(DMSO) and 0.1% fraction V of bovine serum albumin (BSA) and 4 mM HCl.
2.2. Western blotting
Rabbit polyclonal anti-human antibodies for phosphorylated Smad2 (#3101S) and
Smad3 (#9514S) and total Smad2 (#51-1300, Zymed laboratories), Smad3 (#AB3817,
Chemicon International, Temecula, CA), Smad4 (# 9515, Cell Signaling Technology,
Beverly MA, 1:400 dilution) and Smad7 (H-79, Santa Cruz Biotechnology Inc., Santa
Cruz CA) were used as before at dilutions (mostly 1:400) recommended by the
manufacturers. For TIMP-3 protein levels, total cellular extracts from human
chondrocytes (20–30 μg) were fractionated by a 15% SDS-PAGE mini gel system (Bio-
Rad Laboratories Canada Ltd., Mississauga ON), transferred to PVDF (Pall Corporation,
Anne arbor, MI) by electroblotting and reactedwith the 1:400 dilution of humanTIMP-3
polyclonal antibody (Chemicon International, Temecula, CA). Subsequently, membranes
were incubated with the anti-rabbit secondary horseradish peroxidase-conjugated
antibody (Promega, Madison WI) and the TIMP-3 protein bands revealed with the
chemiluminescence detection system of Roche Biochemicals (Laval, QC) with their
protocols. In some cases, Western blots were reprobed with monoclonal anti beta-actin
antibody (Clone AC-15, 1: 10,000 dilution, Sigma-Aldrich, Oakville ON).
2.3. Transfections and luciferase assays
Validated Stealth DuoPak Smad2 (#12937-09), Smad3 (#12937-10) and Smad4
(#12938-126) siRNAs and medium-GC content negative control siRNA (#12935-300)
were transfected by calcium phosphate precipitation method for adherent cells in
suspension as described before [33]. Brieﬂy, chondrocytes were released by trypsiniza-
tion and 2.5×105 cell suspension aliquots incubated with 70 μl siRNA (200–250 nM)-
calcium phosphate precipitate for 25 minwith gentle agitation every 5 min, 1 ml of 10%d Smad2 phosphorylation and TIMP-3 protein expressionwithout affecting constitutive
either treated with vehicle (DMSO and PBS with 0.1% BSA and 4 mM HCl) as control or
stimulated with TGF-β for 20 min (Smad2 and Smad3) or 24 h (TIMP-3). A) Upper two
s while C) lower two panels represent TIMP-3 and beta-actin Western blots. The lower
levels in percentage. Data are presented as the mean±SEM of three independent
Fig. 2. Smad2-speciﬁc siRNA and not its negative control siRNA suppresses Smad2
expression and TGF-β-induced TIMP-3 protein expression in human knee chondrocytes
without affecting constitutive beta-actin levels. Articular chondrocytes were either
treated with vehicles (Control) or transfectedwith 200 nM of negative control or Smad2
small interfering RNA (siRNA) and then exposed to TGF-β for 24 h. The panels represent
Smad2 (upper), Smad3 (middle), TIMP-3 and beta-actin (lower) western blots. The
bottom graph shows normalized densitometric values of Smad-2, Smad3 and TIMP-3
protein levels in percentage. Data are presented as themean±SEM of three independent
experiments. Pb0.05 was considered signiﬁcant.
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adherence. Medium was removed, cells washed with PBS and allowed to recover for
24 h in serum-containing medium. Subsequently, cells were maintained in serum-free
medium for 24 h and then stimulated with TGF-β for 24 h. Due to absence of matrix
during the transfection of suspended chondrocytes, this method results in 80%
transfection efﬁciency as determined with a ﬂuorescent double-stranded RNA
oligonucleotide. In other experiments, 2 μg of TIMP-3 promoter luciferase (−940 to +
376 region) [34], cytomegalovirus (CMV)-driven Renilla luciferase (0.2 μg, transfection
control) and respective siRNA (200 nM) were cotransfected by the modiﬁed calcium
phosphate procedure and after recovery, stimulated with TGF-β and luciferase acti-
vity measured with Promega Dual-Luciferase Reporter assay System (Promega,
Madison WI) and Turner Designs Luminometer TD-20/20 as recommended.
2.4. Construction of promoter deletions and analysis
The original TIMP-3 promoter plasmid obtained from Dr Jean Bennet [34] was a Sac I-
Sac I fragment from −940 to +376 regions. To generate shorter 5′ fragments, the sequence
was entered in the http://rebase.neb.com (New England Biolabs) database to ﬁnd unique
restriction sites. Three unique sites including Asc I (at position −167), MSc I (at position
−333) andKpn I (at position −828)were foundand conﬁrmedby double restriction enzyme
digestion (each of the three enzymes andHind III site in thepolylinker region of pGL-3basic
vector) and 1.5% agarose gel analysis. The Asc I-Hind III (−167 to +376), MSc I-Hind III (−333
to+376) andKpn I-Hind III (−828 to+376)wereelutedandcloned into thepolylinker sites of
pGL3-Basic. Cloning of the three fragments was conﬁrmed by rapid plasmid extraction and
double digestion with Kpn I-Hind III analysis of numerous clones, along with the original
TIMP-3 promoter plasmidwith the Hind III and respective enzymes. These constructs were
puriﬁed by Qiagen QIAﬁlter Plasmid Midi Kit (Qiagen Inc. Canada, Mississauga ON) and
transfected as described above.
2.5. Chromatin Immunoprecipitation (ChIP) analysis
Control and TGF-β stimulated chondrocytes were ﬁxed with 1% formaldehyde
treatment, cross-linked chromatin prepared with ChIP-IT and sheared with enzymatic
shearing kit (Active Motif Cat#53006 and 53007) and DNA-protein complexes
immunoprecipitated with the negative control IgG or with Smad2, Smad3, Smad4 or
Sp1 antibodies. After proteinase K digestion, extraction and puriﬁcation of DNA, TIMP-3
promoter fragments were ampliﬁed by PCR with the TIMP-3 promoter-speciﬁc primers
from the −167 (5′CGC GCC CCA GCC CAC CCA CT 3′), −333 (5′CCA CCC CTC ACC TGT GGA
AG 3′) and −940 (5′CTG TCA GCC ATG GGC AGG GA 3′) and +1 (5′GGG CCC GCC CCC TCA
GAC CA 3′) regions and fragments detected by 2% agarose gel analysis.
All the experimentswereperformedat least 3 times and the resultswere reproducible.
3. Results
3.1. Role of Smad2 phosphorylation in TGF-β-stimulated TIMP-3
induction in human chondrocytes
To investigate the possible involvement of Smad2 in TGF-β-induced
TIMP-3 gene expression, chondrocytes were pretreated with previously
known inhibitors of Smad2/3 phosphorylation [35], PD169316 and
SB203580 as well as their inactive analogue, SB202474 for 1 h and then
stimulatedwith TGF-β for20min.As shown in Fig.1A, TGF-β-stimulated
Smad2 phosphorylation was inhibited by the 10-μM dose of PD169316
and SB203580 but not by SB202474. The levels of total smad2 remained
relatively constant (Fig. 1A, lower panel). In contrast, Smad3 phosphor-
ylationwas not inhibited (Fig.1B). Thus, the role of Smad2 phosphoryla-
tion could be tested with these pharmacological inhibitors.
To further investigate the role of Smad2/3 in TIMP-3 gene re-
gulation, chondrocytes were pretreated for 60minwith the pre-tested
pharmacological inhibitors and then stimulated with TGF-β for 24 h.
Analogous to the results of Smad2, TGF-β-induced TIMP-3 protein
expression could be inhibited by the Smad2/3 phosphorylation inhi-
bitors, PD169316 and SB203580 but not by the inactive homologue,
SB202474. The levels of constitutively expressed β-actin levels re-
mained unaffected (Fig.1C). As these inhibitors are also known to block
p38 phosphorylation, role of Smad2 was further explored by the more
speciﬁc genetic approach of RNA interference (RNAi).
3.2. Blockade of TGF-β-stimulated TIMP-3 increase by Smad2 siRNA-
mediated knockdown
We recently modiﬁed the classical Calcium phosphate transfection
procedure to conduct highly efﬁcient transfections in chondrocytes by
ﬁrst releasing them from their matrix and then transfecting withnucleic acids in cell suspension, followed by their re-adherence in
monolayers [33]. Transfection of Smad2-speciﬁc siRNA resulted in
Smad2 knockdown without affecting the Smad3 expression. Smad2-
deﬁcient chondrocytes displayed severe down-regulation of TIMP-3
induction. Non-speciﬁc negative control siRNA did not affect Smad2 or
Smad3 expression or TIMP-3 induction, thus demonstrating speciﬁc
effects of Smad2 siRNA. The levels of β-actin were not affected by any
of the treatments (Fig. 2).
3.3. Suppression of TGF-β-induced TIMP-3 expression by speciﬁc
inhibitor of Smad3 (SIS3)
Weinvestigated the role of other stimulatory Smad, Smad3, inTIMP-3
induction. Jinnin et al have recently described the speciﬁc inhibitor of
Smad3 (SIS3), which selectively abrogates Smad3 phosphorylation
without affecting Smad2 activation [36]. Pretreatment with SIS3 dose-
dependently inhibited TGF-β-induced Smad3 phosphorylation without
effecting Smad2 phosphorylation (Fig. 3A). TIMP-3 protein (Fig. 3B)
induction was similarly inhibited without affecting the β-actin (Fig. 3B)
levels.
3.4. Abrogation of TGF-β-induced TIMP-3 expression by Smad3 siRNA
To further validate the role of Smad3 in TIMP-3 induction by the
recently introduced genetic tool of RNA interference, chondrocytes
were transfected with Smad3 siRNA or its negative control and then
induced with TGF-β. Smad3 siRNA but not its negative control siRNA
Fig. 3. Speciﬁc inhibitor of Smad3 (SIS3) dose-dependently inhibits TGF-β-induced Smad3 activation and TIMP-3 protein expression in human knee chondrocytes. Quiescent
chondrocytes were either treated with vehicle (control) or pretreated with 5 or 10 µM of SIS3 alone for 60 min and then stimulated with TGF-β for 20 min (A) or 24 h (B). In A) upper
and lower panels represent phosphorylated and total Smad3 levels respectively. Phosphorylated and total Smad2 levels are also depicted. Smad3 phosphorylation and TIMP-3
inhibition by SIS3 without signiﬁcantly affecting p-Smad2, total Smad2 and constitutive beta actin can be noticed. Graphs A and B show normalized densitometric values of pSmad-3,
p-Smad2 and TIMP-3 proteins respectively in percentage. Data are presented as the mean±SEM of three independent experiments. Pb0.05 was considered signiﬁcant.
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pression. Neither Smad2 activation, nor its expression was affected
(Fig. 4A). Induction of TIMP-3 was abolished by Smad3 siRNA but not
by the negative control siRNA (Fig. 4B). The levels of β-actin in these
extracts remained constant.
3.5. Inhibition of human TIMP-3 promoter activity by Smad2 and Smad3
siRNAs
To gain further insight into the mechanism of Smad-mediated
TIMP-3 regulation, we cotransfected chondrocytes with Smad2 or
Smad3 siRNA separately along with the human TIMP-3 promoter
(−940 to +376)-luciferase construct [34] followed by induction with
TGF-β. As reported previously, TGF-β induces TIMP-3 promoter-
driven luciferase activity [32]. Negative control siRNA had very little
effect while Smad2 or Smad3 siRNAs signiﬁcantly inhibited promoter
activity (Fig. 5). These results with exogenous TIMP-3 promoter mimic
the endogenous pattern of TIMP-3 protein expression.
3.6. Inhibition of TGF-β-stimulated TIMP-3 enhancement by Smad4
siRNA
Because stimulatory Smad2 and Smad3 interact with co-Smad4 for
TGF-β signal transduction, we investigated the role of Smad4 in TIMP-
3 induction. Transfection of Smad4 siRNA resulted in abrogation of the
corresponding protein expression that was not affected by the ne-
gative control siRNA. Smad4-speciﬁc siRNA and not its negative con-
trol siRNA diminished TGF-β-induced TIMP-3 protein expression in
human knee chondrocytes without affecting the constitutive β-actin,
Smad2 and Smad3 levels (Fig. 6).
3.7. Identiﬁcation of TGF-β responsive TIMP-3 promoter
Considering the responsiveness of the larger (−940 to +376) human
TIMP-3 promoter to TGF-β, we investigated the identity of shorter regionresponsible for TIMP-3 induction by this growth factor. Using the
convenient restriction enzyme sites, we constructed a series of TIMP-3
promoter deletion mutants. They span −828 to +376 (named Δ −828),
−333 to +376 (named Δ −333) and −167 to +376 (called Δ −167) regions
(Fig. 7A). Functional signiﬁcance of these promoter mutants was tested
by transient transfections and analysis of luciferase activity, which
revealed that −828 deletion retained the original promoter activity
while −333 and −167 deletions displayed somewhat reduced activity.
Thus, most of the TGF-β-responsive region is localized within the −333
region and additional cis-acting elementsmay be present in the upstream
regions (Fig. 7B).
3.8. Conﬁrmation of Smad interaction with the TIMP-3 promoter by ChIP
analysis
To investigate whether Smads indeed bind with the TIMP-3 pro-
moter region in vivo, chromatin from untreated and TGF-β-treated
chondrocytes was immunoprecipitated with different Smad antibo-
dies. Analysis of DNA in the DNA-protein complex with speciﬁc pri-
mers (−940 to +1, −333 to +1 and −176 to +1) revealed that Smad2 and
Smad4 antibodies were able to immunoprecipitate −940 and −333
TIMP-3 promoter fragments, thus conﬁrming binding. The expected
Smad3 binding could not be demonstrated possibly due to lack of ChIP-
quality antibody. All the three fragments contain Sp1 binding sites and
therefore immunoprecipitated with the Sp1 antibody. This served as
positive control of the technique (Fig. 8).
4. Discussion
TGF-β is an important growth factor for cartilage development
(chondrogenesis), itsmaintenance and regeneration [7]. Similarly, TIMP-3
is amajornatural inhibitorofMMPs, aggrecanases andTACE, the enzymes
implicated in cartilage degradation and joint inﬂammation respectively.
By several pharmacological and genetic approaches, we have demon-
strated for the ﬁrst time that Smad2, −3 and −4 are pivotal mediators of
Fig. 4. Smad3-speciﬁc siRNA and not its negative control siRNA suppresses TGF-β-induced Smad3 phosphorylation, Smad3 and TIMP-3 protein expression in human knee
chondrocytes. Articular chondrocytes were either treated with vehicles (Control) or transfected with 200 nM of negative control or Smad3 small interfering RNA (siRNA) and then
exposed to TGF-β for 24 h. In A) speciﬁc inhibition of phosphorylated (p-Smad3) and total Smad3 is shownwithout any affect on p-Smad2, Smad2 and beta-actin level. In B), besides
Smad3 (upper panel) and TIMP-3 (middle panel) suppression by Smad3 siRNA, the unaffected Smad2 and beta-actin (lower panel) Western blots are depicted. Graphs A show
normalized densitometric values of pSmad-3/beta actin, Smad-3/beta actin and pSmad2/total Smad2 in percentage where as graph B shows Smad-3, Smad2 and TIMP-3 protein
levels. Data are presented as the mean±SEM of three independent experiments. Pb0.05 was considered signiﬁcant.
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We have further shown that the regulation is approximately 50% at the
promoter level andmost of the TGF-β responsive elements could be found
within the −333 to +1 region of the promoter where Smads bind in vivo.
Inhibition of TIMP-3 induction by pharmacological inhibition of
Smad2 and Smad3 phosphorylation strongly suggested the implica-
tion of these Smads in TIMP-3 regulation. This inhibition was speciﬁc,
as the equivalent amount of an inactive inhibitor did not suppress
Smad2 phosphorylation and TIMP-3 induction. These results were
reinforced by the alternative and more powerful genetic approach of
Smad2 and Smad3 siRNA-mediated knockdown. Similar induction of
endogenous TIMP-3 and exogenous TIMP-3 promoter-luciferase acti-
vity by TGF-β and their inhibition by Smad2 and Smad3 siRNA sug-
gests that TIMP-3 promoter is responsive to these agents and regulation
most probably occurs at the level of promoter as Smad2 and possibly
Smad3 bind with the TIMP-3 promoter sequences. Lack of Smad3
binding in ChIP analysis may be possibly due to quality of the available
Smad3 antibody which is good enough for Western blotting but not for
the ChIP analysis. Thus both receptor-activated stimulatory Smad2 and
Smad3maybe required for TGF-β-inductionof TIMP-3. This is in contrast
with the studies on Smad2 and Smad3 knockout murine embryonic
ﬁbroblasts where only Smad2 was required for MMP-2 and only Smad3
was needed for c-fos, Smad7 and TGF-β gene expression [37].
Smad2 phosphorylation is reduced during the progression of
murine OA [38]. Smad2 deﬁciency delays TGF-β-mediated Meckel's
cartilage development showing its strong association with different
types of cartilage [39]. In this respect, it is interesting to note thatSmad3 knockout mice display enhanced chondrocyte maturation and
develop osteoarthritis-like degenerative symptoms, suggesting that
Smad3 is required for the maintenance of articular cartilage [30,40].
Smad3 overexpression in mesenchymal stem cells leads to primary
chondrogenesis [41]. TGF-β binding of an ECM protein, asporin, with
aspartic acid repeats polymorphism leads to greater inhibition of TGF-
β signaling and increased susceptibility of certain Japanese patients to
hip and knee OA [42]. Diminished TGF-β receptor in older mice may
be one of the causes of OA development [43]. Thus lack or alteration in
TGF-β signaling and its target genes could severely impair the car-
tilage homeostasis. Indeed, TIMP-3 knockout mice display increased
collagen and aggrecan degradation with aging in a manner similar
to osteoarthritic patients [24]. In a gene array study, TIMP-1 was
found to be a target of Smad3 in human dermal ﬁbroblasts [44]. Smads
were also shown to bind with the rat TIMP-1 promoter [45]. Smad
signaling is also required for TGF-β induction of MMP-1 and MMP-13
in chondrocytes, squamous carcinoma cells and dermal ﬁbroblasts
[46-48].
Smad4 interaction with Smad2/3 is required for TGF-β signal
transmission [49]. Constitutive Smad4 protein expression is in agree-
ment with a previous study where Smad4 mRNA expression was
shown in both normal and OA chondrocytes without any major
differences [50]. Coordinate inhibition of TIMP-3 in Smad4-depleted
cells strongly support the requirement of Smad4 for induction of TIMP-
3 by TGF-β in articular chondrocytes. This is in contrast with the well-
known TGF-β responsive plasminogen activator inhibitor (PAI) gene,
which is induced in the absence of Smad4 [51], thoughboth Smad3 and
Fig. 6. Smad4-speciﬁc siRNA diminishes Smad4 expression and TGF-β-induced TIMP-3
protein expression in human chondrocytes. Articular chondrocytes were either treated
with vehicles (Control) or transfected with 200 nM of negative control or Smad4 small
interfering RNA (siRNA) and then exposed to TGF-β for 24 h. Speciﬁc inhibition of
Smad4 (upper panel), unaffected Smad2 and Smad3 (middle panels), TIMP-3 sup-
pression and unaffected expression of beta actin (lower panels) by Western immu-
noblotting are depicted. Graph shows normalized densitometric values of Smad-4,
Smad2, Smad3 and TIMP-3 proteins in percentage. Data are presented as the mean±
SEM of three independent experiments. Pb0.05 was considered signiﬁcant.
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animals are dwarf and have disorganized growth plate suggesting its
requirement for hypertrophic chondrocyte differentiation and proper
growth plate organization [53].
The TGF-β responsive elements in human TIMP-3 promoter have
not been deﬁned. Sp1 sites in this fragment are important for its
regulation by ERK and Akt pathways [32,33]. By constructing serial 5′
deletions of the larger TIMP-3 promoter fragment and by conducting
transfections of the deletion mutants, we were able to deﬁne shorter
333 bp TGF-β-responsive region. Additional upstream sequences may
also be important for full responsiveness to TGF-β. This region con-
tains Sp1 and some partial Smad binding elements (SBEs) or CAGACA
boxes. The −167 fragment binds with Sp1 only and not with Smads.
One possibility is that Smad2/3/4 complex binds directly with the 6
potential SBEs located between −240 to −540 region in the TIMP-3
promoter region. ChIP analysis supported this view as Smad2/4 bind-
ing was observed with the −333 and −940 fragments that overlap
with the −240 to −540 region. Alternatively, Smads may also interact
with Sp1 to activate TIMP-3 promoter. Smad3-Sp1 interaction occurs
in the TGF-β-induced tenascin-C promoter [54] and full erythropoie-
tin promoter activity [55] and the well characterized, TGF-β-induced
PAI [56] promoter.
We have previously shown the requirement of Erk and Akt path-
ways for TGF-β induction of TIMP-3. Induction of multiple pathways
by TGF-β in association with TIMP-3 has also been observed in other
systems. Both Smad and p38 pathways independently and additively
regulate excessive deposition of collagen I in hepatic stellate cells
during liver ﬁbrosis [57]. In TGF-β induction of biglycan in pancreatic
cells, p38 was activated downstream of Smad pathway [58]. Aggrecan
induction by TGF-β in chondrocytic cells occurs by cross talk of Smad,
ERK and p38 pathways [59]. Both ERK and Smad2 are activated dur-
ing TGF-β-induced chondrogenesis [60]. Thus multiple pathways and
their interactions may activate the human TIMP-3 gene.
5. Conclusion
Wehave shownbypharmacological inhibition andRNA interference-
mediated knockdown approaches that TGF-β receptor-activated Smad2
and Smad3 and co-Smad4 are required for induction of TIMP-3 ex-Fig. 5. Smad2- or Smad3-speciﬁc siRNAs down-regulate TGF-β-induced TIMP-3
promoter-luciferase activity in human chondrocytes. Human knee chondrocytes were
transiently cotransfected with the 2 µg of human TIMP-3 promoter-ﬁreﬂy luciferase
vector, 0.2 µg of a plasmid expressing Renilla luciferase (internal control) and 200 nM
Smad2 or Smad3 siRNA as indicated. Cells were then treated with TGF-β for 24 h.
Extracts were analyzed for luciferase activity. The values of ﬁreﬂy luciferase to Renilla
luciferase ratios were plotted with Prism 3.0 software. Data are presented as the mean±
SEM of three independent experiments. Pb0.05 was considered signiﬁcant.pression and promoter activity by TGF-β. We have also identiﬁed a
shorter TIMP-3 promoter fragment needed for this TGF-β response
where Smad2 andSmad4bind invivo. Thus TIMP-3gene is a target of the
Smad pathway. These mechanisms of TIMP-3 regulation may be pivotal
in TGF-β-stimulated cartilage ECM synthesis, maintenance and repair.
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